A Systematic Literature Review of Pharmacoeconomic Evaluations for Chronic Lymphocytic Leukemia in Europe
Author(s)
Furnback W1, Yang K2, Chuang PY1, Chitale R3, Wang B1, Tang B2
1Elysia Group LLC, Point Pleasant, NJ, USA, 2BeiGene, Ltd., Emeryville, CA, USA, 3Elysia Group LLC, WASHINGTON, DC, USA
OBJECTIVES: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. This study aims to review pharmacoeconomic evaluations of CLL treatments in Europe. METHODS: A systematic literature review was conducted using MEDLINE and EMBASE to identify pharmacoeconomic models evaluating CLL treatments. Studies (including conference abstracts) published 2015-2020 in English were included. Data extracted included countries, interventions, data sources, outcomes, and results. RESULTS: A total of 721 publications were reviewed. There were 21 cost-effectiveness/cost-utility analysis studies (10 manuscripts, 11 abstracts) with 49 separate analyses evaluating cost per life-year (LY) (n=21) or quality-adjusted life-year (QALY) (n=47) involving chemotherapies and newer target therapies. The majority (76%) were industry-sponsored, 7 studies were in the United Kingdom, 2 studies in Portugal, 2 studies in Spain and the rest in 10 other European countries. Markov models were utilized in 12 studies, partition-survival models in 7 studies, and decision-analytic models in 3 studies. For model input, clinical data were from trials and network meta-analyses while utility data were sourced from time trade-off studies to clinical trial patient-reported outcomes. Economic and resource utilization data were mostly from government sources. Study population focused on various CLL populations including first-line only (n=2), relapsed-refractory CLL (n=9), and CLL unsuitable/unable to tolerate fludarabine (n=9). ICERs ranged from €9,445 to €83,435 (€/LY) and €1,263 to €130,563 (€/QALY). There were 4 other studies evaluating budget impact (n=2) or cost comparison/minimization (n=2) in Russia, Portugal, and the Czech Republic. Budget impact ranged from €1.1m (year 1) to €7.2m (year 5) for ibrutinib in the Czech Republic and €22,200 (year 1) to €66,900 (year 5) for ibrutinib + obinutuzumab in Russia. CONCLUSIONS: Recently published pharmacoeconomic analyses in Europe evaluated various treatments for CLL patient populations across 14 different countries. Future economic analyses on recent CLL treatments in more European countries are warranted.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PCN70
Topic
Economic Evaluation
Disease
Oncology